61 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
, even with every 4 weeks dosing, and no significant safety concerns. Taken together, the results further underscore rademikibart’s best-in-biologics … . Rademikibart was generally well tolerated with no unexpected safety signals.
oAnnounced positive long-term data from the China pivotal trial in patients
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
in asthma control occurred early and was sustained through Week 24 for both doses of rademikibart
Safety results suggest rademikibart was generally … from T cell-driven research, announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
efficacy and safety in adult patients with moderate-to-severe persistent asthma.
This Phase 2b trial was a global, multicenter, randomized, double-blind … was started during the
worldwide COVID-19 pandemic and COVID-19 adverse events were noted across all treatment groups. No new safety signals were
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
in terms of safety, quality and efficacy for use in such Region by the applicable Regulatory Authority pursuant to the then-current Regulatory Approval … of human subjects that is designed to (a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety
6-K
4cx283up38c3z6g
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.2
c6wh ng91
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.1
ygg wk8z7
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
h0ztkx
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
u7ta21hyclsv08 yu
23 Jun 23
House Lease Contract
4:31pm
6-K
EX-99.1
xd7fij1
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
nxv8q2j
1 Jun 23
Current report (foreign)
4:24pm
6-K
n1dd0w
1 Jun 23
Current report (foreign)
4:24pm
6-K
a8vvbfry1pe 4otv2e1g
4 Oct 22
Current report (foreign)
7:16am
6-K
EX-99.1
j7ovn7x
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
817es7 h29c4a4ce7q
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
289xw0x01
30 Aug 22
Current report (foreign)
4:01pm
6-K
0g8obhtu
11 Jul 22
Current report (foreign)
4:30pm
F-3/A
ffe9ii86ql9ull rnk
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm